HomeIndustriesHealthcareCytokinetics (CYTK) CEO On Future Of Heart Disease Treatment

Cytokinetics (CYTK) CEO On Future Of Heart Disease Treatment

Cytokinetics (CYTK) CEO Robert Blum joins Nicole Petallides to give an overview of the company and discusses its Aficamten trial. He talks about how the Sequoia-HCM Phase 3 clinical trial showed the best-case scenario result for obstructive hypertrophic cardiomyopathy. He goes over the future of heart disease treatment. Cytokinetics is a biopharma company with a focus on muscle activators and inhibitors as potential disease treatments. Tune in to find out more about the stock market today.

Trading 360

03 Jan 2024

SHARE

ON AIR
1:30 am
Gamma On
replay
12:00 am
Gamma On
REPLAY
12:30 am
Gamma On
REPLAY
1:00 am
Gamma On
REPLAY
ON AIR
1:30 am
Gamma On
REPLAY
2:30 am
Gamma On
REPLAY
3:00 am
Gamma On
REPLAY
3:30 am
Gamma On
REPLAY
4:00 am
Gamma On
REPLAY
5:00 am
Gamma On
REPLAY
6:00 am
Gamma On
REPLAY
education
7:00 am
Inside the Mind of a Trader
REPLAY
education
7:30 am
Inside the Mind of a Trader
REPLAY
education
8:00 am
Inside the Mind of a Trader
REPLAY
8:30 am
Market Overtime
REPLAY
education
9:00 am
Your First Trade
REPLAY
education
9:30 am
Your First Trade
REPLAY
education
10:00 am
Your First Trade
REPLAY
education
10:30 am
Your First Trade
REPLAY
education
11:00 am
Your First Trade
REPLAY
11:30 am
Market Overtime
REPLAY
12:00 pm
Gamma On
REPLAY
12:30 pm
Gamma On
REPLAY
1:00 pm
Gamma On
REPLAY
1:30 pm
Gamma On
REPLAY
2:30 pm
Gamma On
REPLAY
3:00 pm
Gamma On
REPLAY
3:30 pm
Gamma On
REPLAY
4:00 pm
Gamma On
REPLAY
5:00 pm
Gamma On
REPLAY
6:00 pm
Gamma On
REPLAY
7:00 pm
Market Overtime
REPLAY
7:30 pm
Market Overtime
REPLAY
8:00 pm
Market Overtime
REPLAY
8:30 pm
Market Overtime
REPLAY
9:00 pm
Trading 360
REPLAY
10:00 pm
Fast Market
REPLAY
11:00 pm
Next Gen Investing
REPLAY

Schwab Network's Newsletters

Daily insights for every investor